# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K050709   
B. Purpose for Submission: Seek clearance for a modification to a current   
C. Measurand: Normal and abnormal hemoglobin   
D. Type of Test: Semi-Quantitative isoelectric focusing assay   
E. Applicant: Wallac Oy   
F. Proprietary and Established Names: Resolve Hemoglobin Kit JB-2 Staining System

# G. Regulatory Information:

1. Regulation section:   
21 CFR 864.7415

2. Classification: Class II

3. Product code: GKA

4. Panel:

# 81 Hematology

# H. Intended Use:

1. Intended use(s):

The RESOLVE Systems Hemoglobin kit is designed to separate whole blood, cord blood or dried blood spot specimen for detection of normal and variant hemoglobins by isoelectric focusing.

2. Indication(s) for use:

The assay is intended for use as an aid in the diagnosis of neonatal and adult hemoglobinopathies.

3. Special conditions for use statement(s):

4. Special instrument requirements:

The kit is designed to be run on a flat-bed electrofocusing unit.

# I. Device Description:

The RESOLVE Hemoglobin kit is available in 3 configurations (120 tests, 360 tests, 3600 tests). Each kit contains:

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>135 Tests</td><td rowspan=1 colspan=1>360 tests</td><td rowspan=1 colspan=1>3600tests</td></tr><tr><td rowspan=1 colspan=1>Agarose IEF Gel</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Anode Solution</td><td rowspan=1 colspan=1>30 ml</td><td rowspan=1 colspan=1>120 ml</td><td rowspan=1 colspan=1>480ml</td></tr><tr><td rowspan=1 colspan=1>Cathode Solution</td><td rowspan=1 colspan=1>30 ml</td><td rowspan=1 colspan=1>60 ml</td><td rowspan=1 colspan=1>240 ml</td></tr><tr><td rowspan=1 colspan=1>HB Elution Solution</td><td rowspan=1 colspan=1>30 ml</td><td rowspan=1 colspan=1>30 ml</td><td rowspan=1 colspan=1>240 ml</td></tr><tr><td rowspan=1 colspan=1>IEF Electrode Wicks</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>2 X 80</td></tr><tr><td rowspan=1 colspan=1>BlottinggPapers</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Blotting Strips</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>Sample Application Templates</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>Order separately</td><td rowspan=1 colspan=1>Order separately</td></tr></table>

# J. Substantial Equivalence Information:

1. Predicate device name(s):

BioRad VARIANT Sickle Cell Short Program

BioRad Variant nbs Sickle Cell Program

2. Predicate 510(k) number(s):

K924813   
K051072

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=5>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>VARIANTSickle CellShort Program</td><td rowspan=1 colspan=1>VARIANTnbs SickleCell Program</td></tr><tr><td rowspan=3 colspan=1>Intended Use</td><td rowspan=3 colspan=1>To separatewhole blood,cord blood ordried bloodspot specimenfor detectionof normal andvarianthemoglobins</td><td rowspan=2 colspan=2>Qualitativescreen for thepresence ofhemoglobin&#x27;sF, A, S, D, Cand E ineluates of</td><td rowspan=3 colspan=1>Qualitativescreen for thepresence ofhemoglobinsF, A, S, D, Cand E ineluates ofneonatal bloodcollected onfilter paper</td></tr><tr><td rowspan=1 colspan=1>eluates of</td></tr><tr><td rowspan=1 colspan=2>neonatal bloodcollected onfilter paper</td></tr><tr><td rowspan=1 colspan=1>Analytesidentified</td><td rowspan=1 colspan=1>HemoglobinsF,A,E,D,S,C.In addition Gand α- and β-thalassemia</td><td rowspan=1 colspan=2>HemoglobinsF,A,E,S,S andC</td><td rowspan=1 colspan=1>HemoglobinsF,A,E,D,S andC</td></tr></table>

<table><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">VARIANTSickle CellShortProgram</td><td colspan="1" rowspan="1">VARIANT nbsSickle CellProgram</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Neonataldried bloodspots,wholeblood andcord blood</td><td colspan="1" rowspan="1">Dried bloodspots</td><td colspan="1" rowspan="1">Dried bloodspots</td></tr><tr><td colspan="1" rowspan="1">TargetPopulation</td><td colspan="1" rowspan="1">Neonatesand adults</td><td colspan="1" rowspan="1">Neonates</td><td colspan="1" rowspan="1">Neonates</td></tr><tr><td colspan="1" rowspan="1">Principle</td><td colspan="1" rowspan="1">IEF</td><td colspan="1" rowspan="1">HPLC</td><td colspan="1" rowspan="1">HPLC</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

# L. Test Principle:

Whole blood or cord blood, on a filter spot or collected into an EDTA or heparinized tube, is treated with a Hb Elution Solution to inhibit methemoglobin formation. The solution is then placed on an agarose gel containing RESOLVE Ampholytes $\mathsf { p H } 6 { - } 8$ , and the gel is placed on the electrofocusing unit.

When an electrical current is applied to the gel, the hemoglobin variants possessing individual isoelectric points (pl’s), migrate through the gel. When an individual variant’s pl equals the pH in the gel, it ceases migration and forms a discrete band. When all hemoglobin bands have focused, the gel is fixed in trichloroacetic acid.

Hemoglobin bands can be visualized by using the JB-2 Staining System. Stained or unstained gels can be scanned by a densitometer to estimate the percentages of normal and variant hemoglobins.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Variation was estimated by measuring the distance of certain Hb bands of FASC controls used in the comparison studies. The analysis of variance was used to calculate the following:

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">Averagedistance (mm)</td><td colspan="1" rowspan="1">Within-gelprecision(CV%)</td><td colspan="1" rowspan="1">Between-gelPrecision(%CV)</td><td colspan="1" rowspan="1">Total precisionWithin laboratory(%CV)</td></tr><tr><td colspan="1" rowspan="1">HbA1c VS.Hb C</td><td colspan="1" rowspan="1">216</td><td colspan="1" rowspan="1">17.8</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">2.8</td></tr><tr><td colspan="1" rowspan="1">Hb A vs.Hb F</td><td colspan="1" rowspan="1">223</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">4.4</td></tr></table>

b. Linearity/assay reportable range:

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

d. Detection limit:

e. Analytical specificity:

f. Assay cut-off:

2. Comparison studies:

a. Method comparison with predicate device:

The RESOLVE Hemoglobin system was compared to HPLC. Samples included $60 \%$ from normal patients, $20 \%$ from hemoglobin combinations having Hb S and $20 \%$ from other hemoglobin variants to include Hb C, D, E, GPhiladelphia, $\mathfrak { a }$ -thalassemia and $\beta$ -thalassemia.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>HPLC</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>Lower 95% CI</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>850</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>837</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.7</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>1031</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=1>98.4</td></tr></table>

b. Matrix comparison:

3. Clinical studies:

a. Clinical Sensitivity:

b. Clinical specificity:

c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off:

5. Expected values/Reference range:

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.